Zenas BioPharma: Strategic Licensing and Clinical Advancements Justify Buy Rating

Retrieved on: 2025-10-10 16:58:07

Tags for this article:

Click the tags to see associated articles and topics

Zenas BioPharma: Strategic Licensing and Clinical Advancements Justify Buy Rating. View article details on hiswai:

Excerpt

Analyst Judah Frommer from Morgan Stanley maintained a Buy rating on Zenas BioPharma, Inc. and keeping the price target at $31.00.

Article found on: www.tipranks.com